Table 1.
Risk of therapy-related myeloid neoplasms in breast cancer patients receiving adjuvant chemotherapy with alkylating agents.
| Reference | Breast cancer patients (n) | Therapy | t-MN (n) | Cumulative risk (%) |
|---|---|---|---|---|
| Valagussa et al, 1994 [36] | 2465 | CMF | 3 | 0.23 (at 15 y) |
| Bernard-Marty et al, 2002 [34] | 255 | CMF | 0 | 0 (at 5 y) |
| Praga et al, 2005 [37] | 1427 | CMF | 1 | 0.07 (at 8 y) |
| Ejlertsen et al, 2007 [24] | 629 | CMF | 2 | nr |
| Hershman et al, 2007 [40] | 3330 | Cyclophosphamide-based regimens | 40 | 1.20 |
CMF: cyclophosphamide, methotrexate, and fluorouracil; nr: not reported.